Microbion Corporation has introduced a groundbreaking innovation in the fight against chronic pulmonary infections, particularly those associated with cystic fibrosis (CF). Their latest invention, a bismuth-thiol (BT) aerosol composition, represents a novel approach to tackling resistant bacterial infections that compromise lung function in CF patients.

This aerosol formulation consists of liquid droplets dispersed in a gas, with each droplet containing finely suspended particles of bismuth-1,2-ethanedithiol (BisEDT). What sets this technology apart is the meticulous control of particle size, ensuring optimal deposition in the deep lung region. With at least 70% of the droplets achieving a mass median aerodynamic diameter (MMAD) between 0.4 and 5 micrometers, the aerosol is engineered for maximum therapeutic efficacy.

The innovative composition enhances the stability and bioavailability of BisEDT, a compound known for its potent antimicrobial properties. Unlike traditional antibiotics, which often struggle to penetrate bacterial biofilms, BisEDT demonstrates a sustained half-life of up to four days in the lungs, ensuring prolonged antimicrobial activity against even the most persistent pathogens, including Pseudomonas aeruginosa and multi-drug resistant (MDR) strains.

Addressing a critical unmet need, this aerosol therapy provides CF patients with a promising alternative to conventional inhaled antibiotics. Its broad-spectrum activity, resistance to bacterial degradation, and extended lung retention could revolutionize the management of chronic pulmonary infections. By minimizing the frequency of administration and improving patient adherence, Microbion’s innovation has the potential to significantly enhance quality of life for those battling CF-related respiratory complications.

With this pioneering advancement, Microbion Corporation continues to push the boundaries of medical science, offering new hope to individuals facing the challenges of chronic lung infections.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.